Table 2 Clinical characteristics of the training and validation sets
Clinical | Type | Total | Validation | Train | p value |
|---|---|---|---|---|---|
Age |  <  = 65 | 153 (42.15%) | 52 (45.61%) | 101 (40.56%) | 0.4294 |
|  |  > 65 | 210 (57.85%) | 62 (54.39%) | 148 (59.44%) |  |
Gender | Female | 167 (46.01%) | 48 (42.11%) | 119 (47.79%) | 0.3706 |
| Â | Male | 196 (53.99%) | 66 (57.89%) | 130 (52.21%) | Â |
Stage | Stage I | 63 (17.36%) | 21 (18.42%) | 42 (16.87%) | 0.9773 |
| Â | Stage II | 140 (38.57%) | 44 (38.6%) | 96 (38.55%) | Â |
| Â | Stage III | 98 (27%) | 31 (27.19%) | 67 (26.91%) | Â |
| Â | Stage IV | 51 (14.05%) | 15 (13.16%) | 36 (14.46%) | Â |
| Â | Unknow | 11 (3.03%) | 3 (2.63%) | 8 (3.21%) | Â |
T | T1 | 9 (2.48%) | 2 (1.75%) | 7 (2.81%) | 0.3358 |
| Â | T2 | 65 (17.91%) | 20 (17.54%) | 45 (18.07%) | Â |
| Â | T3 | 249 (68.6%) | 74 (64.91%) | 175 (70.28%) | Â |
| Â | T4 | 39 (10.74%) | 17 (14.91%) | 22 (8.84%) | Â |
| Â | Unknow | 1 (0.28%) | 1 (0.88%) | 0 (0%) | Â |
M | M0 | 272 (74.93%) | 87 (76.32%) | 185 (74.3%) | 0.8425 |
| Â | M1 | 51 (14.05%) | 15 (13.16%) | 36 (14.46%) | Â |
| Â | Unknow | 40 (11.02%) | 12 (10.53%) | 28 (11.24%) | Â |
N | N0 | 217 (59.78%) | 67 (58.77%) | 150 (60.24%) | 0.8998 |
| Â | N1 | 84 (23.14%) | 26 (22.81%) | 58 (23.29%) | Â |
| Â | N2 | 62 (17.08%) | 21 (18.42%) | 41 (16.47%) | Â |